Valneva Initiates Phase 3 Clinical Study for its Chikungunya Vaccine Candidate VLA1553

by NASDAQ Market News September 8, 2020

NASDAQ Market News
Click here to email author

Novartis data at ACTRIMS-ECTRIMS highlight the strength of leading multiple sclerosis (MS) portfolio with life-changing therapies for people across the MS spectrum

Everest Medicines Announces First Patient Randomized in a Phase 3 Clinical Study of Nefecon for IgA Nephropathy Patients in China

Ads